Podcasts about perampanel

  • 5PODCASTS
  • 7EPISODES
  • 16mAVG DURATION
  • ?INFREQUENT EPISODES
  • Jan 2, 2024LATEST

POPULARITY

20172018201920202021202220232024


Best podcasts about perampanel

Latest podcast episodes about perampanel

Neurology Minute
Anti-Seizure Medications: Part 2

Neurology Minute

Play Episode Listen Later Jan 2, 2024 1:34


In the second part of this three-part series, Dr. Iran Sheikh explores the realm of anti-seizure medications. In this installment, he shifts his focus to Perampanel.

MDS Podcast
Perampanel may reduce alpha-synuclein transmission in Parkinson's disease. A possible therapeutic target?

MDS Podcast

Play Episode Listen Later Oct 18, 2021


Dr. Michele Matarazzo speaks with Prof. Ryosuke Takahashi about the results of his recent study that shows how this anti-epileptic drug may inhibit the transmission of alpha synuclein in PD. While this was tested in animal models, future clinical trials are warranted to test the effects on PD progression. Read the article

CReATe Connect Podcast
ALS Untangled Series: Ep. 17 – Perampanel

CReATe Connect Podcast

Play Episode Listen Later Jul 17, 2019 16:42


Perampanel (also called Fycompa) is a drug used to treat epileptic seizures. Here we review the reasons it might be useful in slowing ALS progression and describe what happened when ALS mice and a small number of people with ALS were treated with this and similar drugs. We describe the ongoing ALS trials and review safety and dosing considerations.

CReATe Connect Podcast
ALS Untangled Series: Ep. 17 – Perampanel

CReATe Connect Podcast

Play Episode Listen Later Jul 17, 2019 16:42


Perampanel (also called Fycompa) is a drug used to treat epileptic seizures. Here we review the reasons it might be useful in slowing ALS progression and describe what happened when ALS mice and a small number of people with ALS were treated with this and similar drugs. We describe the ongoing ALS trials and review safety and dosing considerations.

Neurology® Podcast
April 1 2014 Issue

Neurology® Podcast

Play Episode Listen Later Mar 31, 2014 29:46


1) Rolandic epilepsy has little effect on adult life 30 years later and 2) Topic of the month: Therapeutics in epilepsy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Nathan Fountain interviews Drs. Carol and Peter Camfield about their paper on how rolandic epilepsy had little effect on adult life 30 years later. Dr. Adam Numis is reading our e-Pearl of the week about lower cranial nerve dysfunction. In the next part of the podcast Dr. Lara Marcuse interviews Dr. Jacqueline French about epilepsy therapeutics: Perampanel. There is different intro music, "Goofy Vocal Groove" by Dave Girtsman in this podcast. The song may be found at http://freemusicarchive.org/music/Dave_Girtsman/Silly_Songs/11_-_dave_girtsman_-_goofy_vocal_groove_kzz01_vbr. The original work was not changed ii any way and is licensed under a Attribution-NonCommercial-ShareAlike 3.0 International License. The participants had nothing to disclose except Drs. Fountain, Peter Camfield, Numis and French.Dr. Fountain serves as Vice-President of the National Association of Epilepsy Centers; performs EEG lab work and EEG interpretation in his clinical practice (10% effort); receives research support from UCB, SK Life Sciences, Sunovion, Medtronic, NeuroPace; and the NIH.Dr. Peter Camfield serves as an editorial board member of Journal of Child Neurology and Pediatric Neurology Epileptic Disorders Journal.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. French serves as an Associate Editor for Epilepsia; serves as an editorial board member of Lancet Neurology, Neurology Today, Epilepsy Currents; serves on the scientific advisory board for Electrocore, Epilepsy Therapy Project, UCB, Eisai Inc., SK Corporation, Marinus, Upsher-Smith Laboratories, Inc., Sunovion Inc., Vertex Pharmaceuticals, Novartis, Epilepsy Study Consortium; received paid travel to present findings at scientific meetings, present at investigators meetings attend advisory boards or give lectures from Acorda, UCB, Eisai, Inc., Johnson and Johnson, Upsher-Smith Laboratories, Inc., Novartis, Pfizer Inc, Eli Lilly and Company, LCGH, Vertex Pharmaceuticals, Supernus, Marinus Pharmaceuticals, Inc., SK Corporation; receives research support from Eisai, Inc., UCB, SK Corporation, Valeant Pharmaceuticals International, Upsher-Smith Laboratories, Inc., Vertex Pharmaceuticals, Pfizer Inc, Marinus Pharmaceuticals, Brain Sentinal, Epilepsy Research Foundation, The Milken Foundation, The Epilepsy Study Consortium and the NIH.

Epilepsy Talk Radio
Perampanel

Epilepsy Talk Radio

Play Episode Listen Later Oct 24, 2011 17:00


In this episode of Epilepsy.com's Hallway Conversations, Dr. Joseph Sirven, Professor of Neurology at Mayo Clinic Arizona and Editor-in-Chief of Epilepsy.com/Professionals, interviews Gregory Krauss, MD, Professor of Neurology at Johns Hopkins Medical School, about Perampanel.

professor chief md professionals neurology epilepsy sirven krauss johns hopkins medical school mayo clinic arizona perampanel
Epilepsy Talk Radio
Perampanel: A New Antiepileptic Drug

Epilepsy Talk Radio

Play Episode Listen Later Mar 23, 2011 19:00


In this episode of Epilepsy.com's Hallway Conversations, Dr. Joseph Sirven, Professor of Neurology at Mayo Clinic Arizona and Editor-in Chief of Epilepsy.com/Professionals, interviews Gregory Krauss, MD, Professor of Neurology at Johns Hopkins Medical School, about Perampanel, a new antiepileptic drug.

professor chief md drug professionals neurology epilepsy medicines seizures johns hopkins medical school mayo clinic arizona perampanel